Advertisement
Canada markets close in 6 minutes
  • S&P/TSX

    21,797.24
    +88.80 (+0.41%)
     
  • S&P 500

    4,963.00
    -48.12 (-0.96%)
     
  • DOW

    37,975.92
    +200.54 (+0.53%)
     
  • CAD/USD

    0.7272
    +0.0009 (+0.12%)
     
  • CRUDE OIL

    83.27
    +0.54 (+0.65%)
     
  • Bitcoin CAD

    88,347.39
    +1,053.39 (+1.21%)
     
  • CMC Crypto 200

    1,382.50
    +69.88 (+5.32%)
     
  • GOLD FUTURES

    2,406.60
    +8.60 (+0.36%)
     
  • RUSSELL 2000

    1,940.27
    -2.69 (-0.14%)
     
  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     
  • NASDAQ

    15,263.91
    -337.59 (-2.16%)
     
  • VOLATILITY

    18.97
    +0.97 (+5.40%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

Novavax (NVAX) closed the most recent trading day at $7.53, moving -1.31% from the previous trading session. This change lagged the S&P 500's daily loss of 0.38%. At the same time, the Dow lost 0.68%, and the tech-heavy Nasdaq lost 10.47%.

Heading into today, shares of the vaccine maker had gained 23.86% over the past month, outpacing the Medical sector's gain of 4.28% and the S&P 500's gain of 2.61% in that time.

Novavax will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$3.04, down 218.75% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $137.18 million, down 80.51% from the year-ago period.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$5.94 per share and revenue of $969 million. These totals would mark changes of +29.45% and -51.11%, respectively, from last year.

ADVERTISEMENT

Any recent changes to analyst estimates for Novavax should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 5.02% lower within the past month. Novavax is currently a Zacks Rank #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 77, putting it in the top 31% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novavax, Inc. (NVAX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research